货号:A1274889
同义名:
L-651582 Orotate; CAI Orotate
Carboxyamidotriazole Orotate是一种非电压性的钙通道和钙通道介导的信号通路抑制剂,具有抗癌、抗炎和抗血管生成作用。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
p38 MAPK,ERK,ROS | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | Rho,PKA | 98% | ||||||||||||||||
| ML-9 | ✔ | MLCK,Akt | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
L-type calcium channel, IC50: 12.2 μM N-type Ca2+ channel, IC50: 0.11 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | Akt,p38 MAPK | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Carboxyamidotriazole Orotate, the orotate salt of Carboxyamidotriazole (CAI), is recognized for its ability to inhibit signal transduction. It acts as a cytostatic blocker of nonvoltage-operated calcium channels and pathways dependent on these channels, showcasing antitumor, anti-inflammatory, and antiangiogenic properties[1].[2]. |
| 体内研究 | When administered intraperitoneally at doses of 342 and 513 mg/kg on a once-daily schedule for two cycles, Carboxyamidotriazole Orotate exhibits significant antitumor activity in CML xenograft models[1]. |
| 体外研究 | Carboxyamidotriazole Orotate curbs the proliferation of LAMA84R and K562R cell lines within a concentration range of 0.1-10 µM over 24-96 hours[1]. Carboxyamidotriazole Orotate also impedes the phosphorylation of CrkL, a target of Bcr-Abl kinase, with a significant reduction observed upon treatment with 5 µM of Carboxyamidotriazole Orotate[1]. |
| Concentration | Treated Time | Description | References | |
| rat aortic rings | 12 μg/mL | 4 days | as a positive control to evaluate anti-angiogenic properties | Mol Cancer Ther. 2015 Oct;14(10):2228-37 |
| CD8+T cells | 10 μM | 48 h | To evaluate the effect of CAI on IFN-γ production in CD8+T cells, results showed that CAI significantly increased IFN-γ production. | J Immunother Cancer. 2019 Sep 11;7(1):246 |
| B16 melanoma cells | 10 μM | 24 h | To evaluate the effect of CAI on the tumor-killing capability of CTLs, results showed that CAI enhanced the cytotoxic activity of CTLs. | J Immunother Cancer. 2019 Sep 11;7(1):246 |
| C26 cells | 10 μM | 48 h | Measure intracellular ROS levels, results showed that CAI significantly increased ROS accumulation. | Acta Pharm Sin B. 2022 Feb;12(2):759-773 |
| HCT116 cells | 10 μM | 48 h | Evaluate the effect of CAI on glucose uptake, results showed that CAI decreased 2-NBDG uptake. | Acta Pharm Sin B. 2022 Feb;12(2):759-773 |
| Administration | Dosage | Frequency | Description | References | ||
| NOD/Ltj mice | Sjögren's disease-like model | Oral gavage | 20 and 40 mg/kg | Once daily for 16 weeks | CAI augmented salivary secretion, decreased water intake and serum autoantibody levels, suppressed histological alterations and lymphocyte foci, and diminished inflammatory factors such as IL-1β and IL-6. It also blocked IκBα degradation and p65 nuclear translocation. | Int J Med Sci. 2025 Apr 28;22(10):2362-2372 |
| Lewis rats | Adjuvant arthritis (AA) model | Oral | 10, 20, 40 mg/kg | Once daily from day 12 to day 26 | To evaluate the effects of CAI on arthritis index, body weight, joint destruction, and inflammatory cytokine levels in AA rats. CAI significantly decreased the arthritis index, improved body weight loss, reduced joint destruction, and lowered the levels of inflammatory cytokines (IL-1β, IL-6, IL-18, and TNF-α). | Br J Pharmacol. 2015 Jul;172(13):3446-59 |
| C57BL/6 mice | B16 melanoma model | Intragastric injection | 20 mg/kg | Once daily for 23 days | To evaluate the effect of CAI on tumor growth, results showed that CAI significantly delayed tumor growth and prolonged the survival of tumor-bearing mice. | J Immunother Cancer. 2019 Sep 11;7(1):246 |
| BALB/c mice and nude mice | Colorectal cancer xenograft model | Intragastric injection | 20 mg/kg | Once daily for 28 days | Evaluate the antitumor effect of CAI alone or in combination with GLS or GDH1 inhibitors, results showed that combination therapy significantly inhibited tumor growth and prolonged mouse survival. | Acta Pharm Sin B. 2022 Feb;12(2):759-773 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.72mL 0.34mL 0.17mL |
8.61mL 1.72mL 0.86mL |
17.22mL 3.44mL 1.72mL |
|
| CAS号 | 187739-60-2 |
| 分子式 | C22H16Cl3N7O6 |
| 分子量 | 580.76 |
| SMILES Code | O=C(C(NC1=O)=CC(N1)=O)O.O=C(C2=C(N)N(CC3=CC(Cl)=C(C(C4=CC=C(Cl)C=C4)=O)C(Cl)=C3)N=N2)N |
| MDL No. | MFCD22572756 |
| 别名 | L-651582 Orotate; CAI Orotate |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 4 mg/mL(6.89 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
沪公网安备 31011702889066号
沪ICP备2024050318号-1